Kimberly G. Estep
Nycomed
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kimberly G. Estep.
European Journal of Pharmacology | 1994
Douglas S. Krafte; Kathleen Davison; Nancy Dugrenier; Kimberly G. Estep; Kurt Josef; Robert L. Barchi; Roland G. Kallen; Paul J. Silver; Alan M. Ezrin
Pharmacological modulation of human sodium current was examined in Xenopus oocytes expressing human heart Na+ channels. Na+ currents activated near -50 mV with maximum current amplitudes observed at -20 mV. Steady-state inactivation was characterized by a V1/2 value of -57 +/- 0.5 mV and a slope factor (k) of 7.3 +/- 0.3 mV. Sodium currents were blocked by tetrodotoxin with an IC50 value of 1.8 microM. These properties are consistent with those of Na+ channels expressed in mammalian myocardial cells. We have investigated the effects of several pharmacological agents which, with the exception of lidocaine, have not been characterized against cRNA-derived Na+ channels expressed in Xenopus oocytes. Lidocaine, quinidine and flecainide blocked resting Na+ channels with IC50 values of 521 microM, 198 microM, and 41 microM, respectively. Use-dependent block was also observed for all three agents, but concentrations necessary to induce block were higher than expected for quinidine and flecainide. This may reflect differences arising due to expression in the Xenopus oocyte system or could be a true difference in the interaction between human cardiac Na+ channels and these drugs compared to other mammalian Na+ channels. Importantly, however, this result would not have been predicted based upon previous studies of mammalian cardiac Na+ channels. The effects of DPI 201-106, RWJ 24517, and BDF 9148 were also tested and all three agents slowed and/or removed Na+ current inactivation, reduced peak current amplitudes, and induced use-dependent block. These data suggest that the alpha-subunit is the site of interaction between cardiac Na+ channels and Class I antiarrhythmic drugs as well as inactivation modifiers such as DPI 201-106.
Journal of Medicinal Chemistry | 2007
Thomas A. Chappie; John Michael Humphrey; Martin Patrick Allen; Kimberly G. Estep; Carol B. Fox; Lorraine A. Lebel; Spiros Liras; Eric S. Marr; Frank S. Menniti; Jayvardhan Pandit; Christopher J. Schmidt; Meihua Tu; Robert Williams; Feng V. Yang
Archive | 1996
Edward R. Bacon; Sol J. Daum; Kimberly G. Estep
Journal of Medicinal Chemistry | 2000
Kimberly G. Estep; Kurt Josef; Edward R. Bacon; Carl R. Illig; John L. Toner; Dinesh Mishra; William F. Blazak; Dennis M. Miller; David K. Johnson; Jack M. Allen; and Andy Spencer; Susan A. Wilson
Archive | 1993
Edward R. Bacon; Sol J. Daum; Kimberly G. Estep; Kurt A. Josef; Brent D. Douty; Carl R. Illig
Archive | 1993
Kurt A. Josef; Edward R. Bacon; Kimberly G. Estep; Carl R. Illig; Brent D. Douty
Archive | 1995
Carl Sterling Wint R. C. O. Illig; John L. Toner; Edward J. Baker; Robert W. Lee; Tom Caulfield; Brent D. Douty; Kurt Josef; Edward R. Bacon; Kimberly G. Estep; Saul Daum; Eugene R. Cooper
Archive | 1995
Stephen B. Ruddy; Gregory L. McIntire; Mary E. Roberts; John L. Toner; Edward R. Bacon; Tom Caulfield; Eugene R. Cooper; Brent D. Douty; Carl Sterling Wint R. C. O. Illig; Kimberly G. Estep
Archive | 1994
Edward J. Baker; Kurt A. Josef; Edward R. Bacon; Kimberly G. Estep; Carl R. Illig; Brent D. Douty; John L. Toner; Robert W. Lee
Archive | 1994
Edward J. Baker; Robert W. Lee; Edward R. Bacon; Sol J. Daum; Kimberly G. Estep; Kurt A. Josef; Brent D. Douty; Carl R. Illig; John L. Toner